Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)

NCT02013648 is registered in ClinicalTrials.gov with University of Ulm as lead sponsor.

NCT NCT02013648
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02013648 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)
Lead sponsor
University of Ulm
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2014
Completion date
February 29, 2024
Enrollment
204 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml)